As of 2026, no completed randomised controlled trial has evaluated BPC-157 specifically in human rotator cuff tears. The evidence base consists of one direct rat rotator cuff model, multiple preclinical tendon-healing studies, and two recent narrative reviews. A Phase 2 RCT in a related musculoskeletal indication (hamstring strain, NCT07437547) is registered but unpublished.
What Is the Current Evidence Landscape for BPC-157 in Rotator Cuff Pathology?
The evidence landscape in 2026 is entirely preclinical for the rotator cuff indication. A rat supraspinatus tear model demonstrated improved structural healing and functional recovery with BPC-157. No human interventional data for this specific indication exists, and the peptide remains unapproved by any regulatory agency for musculoskeletal use.
The foundational rotator cuff study by Sikiric and colleagues used a surgically induced supraspinatus tear in rats, administering BPC-157 intraperitoneally and observing accelerated tendon-to-bone reattachment alongside improved biomechanical load-to-failure metrics. The authors concluded that the peptide could be “successfully used in healing and functional recovery of rotator cuff tear injury.” This single animal study remains the only direct rotator cuff–specific investigation published to date.
A 2025 PMC narrative review (PMC12446177) surveyed the broader musculoskeletal literature and characterised BPC-157 as demonstrating “robust regenerative and cytoprotective effects in preclinical studies.” The same review explicitly flagged the absence of completed human RCTs as the central limitation preventing clinical translation. A separate 2025 PMC review (PMC12944561) covering tendon, ligament, and muscle injury reached an identical conclusion: multi-modal preclinical efficacy, zero published human trial data.
Which Molecular Mechanisms Are Proposed to Underlie BPC-157 Tendon Effects?
BPC-157 is proposed to act through at least three converging pathways in tendon tissue: upregulation of growth hormone receptor expression in fibroblasts, activation of the FAK-paxillin focal adhesion cascade driving fibroblast migration, and stimulation of VEGF-A-mediated angiogenesis. Each pathway has been characterised in cell culture or rodent models; none has been confirmed in human tendon tissue.
Chang et al. (PMC6271067) demonstrated that BPC-157 dose- and time-dependently increased growth hormone receptor mRNA and protein in tendon fibroblasts, with downstream effects on collagen type I synthesis. This GHR-sensitisation mechanism is considered one of the primary drivers of the accelerated fibroblast proliferation observed across multiple tendon injury models.
The FAK-paxillin pathway was characterised in a Journal of Applied Physiology study showing that BPC-157 promoted ex vivo outgrowth of tendon fibroblasts from explants and enhanced cell survival under oxidative stress. Inhibition of FAK phosphorylation abolished these effects, confirming pathway specificity. The collagen type I/III ratio improvement observed in rodent models is mechanistically consistent with this fibroblast-activation profile.
VEGF-A upregulation has been documented in wound-healing models and is considered central to the early angiogenic response that precedes structural tendon repair. A 2026 MDPI review (PMC13026520) noted that BPC-157 modulates the nitric oxide synthase system in parallel, potentially amplifying the vasodilatory and pro-angiogenic signal. These pathways likely operate concurrently during the proliferative phase of tendon healing.
Does BPC-157 Counteract Corticosteroid-Induced Tendon Damage?
Preclinical data indicate that BPC-157 can partially mitigate corticosteroid-induced impairment of tendon-to-bone healing. The 2025 PMC12944561 review specifically noted that BPC-157 “mitigates the negative effects of corticosteroids on tendon-to-bone healing and counteracts inflammation without impairing angiogenesis.” This interaction is mechanistically plausible but has not been tested in a human rotator cuff context.
Corticosteroid injections remain a standard short-term intervention for rotator cuff tendinopathy despite well-documented catabolic effects on tenocytes and extracellular matrix integrity. The preclinical observation that BPC-157 preserves angiogenesis while suppressing inflammatory signalling suggests a potentially complementary profile. However, the rodent models used to establish this interaction employed systemic corticosteroid administration rather than the localised subacromial injection paradigm used clinically.
Why Is There No Human RCT for BPC-157 in Rotator Cuff Tears?
No human RCT exists for this indication due to regulatory, commercial, and methodological barriers. BPC-157 lacks pharmaceutical approval in any major jurisdiction, limiting formal trial sponsorship. Endpoint selection is also complex: MRI-confirmed re-tear rates and validated functional scores such as ASES or DASH would be required primary outcomes for a structural rotator cuff trial.
The only registered human interventional trial as of 2026 is NCT07437547, a Phase 2 randomised, double-blind, placebo-controlled study evaluating BPC-157 for acute hamstring muscle strain. No results have been published from this trial. The PMC12927661 comparative review of PRP, cell-based, and peptide interventions for chronic rotator cuff tendinopathy characterised peptide-based approaches as representing “a developing approach with preliminary evidence.”
How Should Researchers Appraise the Quality of the Existing BPC-157 Evidence?
The existing evidence for BPC-157 in rotator cuff pathology is uniformly preclinical and carries limitations inherent to rodent tendon models: non-physiological injury induction, absence of the degenerative background typical of clinical presentations, and pharmacokinetic profiles that do not translate directly to human dosing. The two 2025 narrative reviews are non-systematic and cannot support meta-analytic conclusions.
Rodent rotator cuff models differ from human pathology in several structurally important ways. The rat supraspinatus lacks the fibrocartilaginous enthesis complexity of the human tendon-to-bone junction. Surgically induced acute tears do not replicate the chronic degenerative milieu — characterised by hypocellularity, lipid infiltration, and altered matrix metalloproteinase activity — that defines most clinical rotator cuff presentations. Translational fidelity from these models to human outcomes therefore remains uncertain.
The narrative review methodology employed in both PMC12446177 and PMC12944561 introduces selection bias risk; neither review registered a protocol or conducted a systematic database search with PRISMA-compliant reporting. Researchers should treat their conclusions as hypothesis-generating rather than as evidence synthesis. A formal Cochrane-style systematic review of BPC-157 across all tendon indications does not yet exist.
What Is the Regulatory and Approval Status of BPC-157 as of 2026?
BPC-157 holds no approved therapeutic indication in the United States, European Union, or Australia as of 2026. The FDA has not granted IND clearance for any BPC-157 musculoskeletal indication, and the peptide is classified as a research compound. Its compounding and distribution have been subject to increasing regulatory scrutiny across multiple jurisdictions.
In the United States, the FDA placed BPC-157 on its list of bulk drug substances that may not be used in compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This regulatory action cited insufficient evidence of clinical utility alongside unresolved safety data. The decision has materially constrained access through compounding pharmacies.
The European Medicines Agency has not evaluated BPC-157 for any indication, and no Marketing Authorisation Application has been filed as of this writing. The regulatory gap between the preclinical evidence base and the requirements for human trial authorisation remains the primary structural barrier to clinical development in this indication.